Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing sales7@sinochem-nanjing.com
Follow us:

Mirabegron

    • Product Name Mirabegron
    • Alias Myrbetriq
    • Einecs 939-457-4
    • Mininmum Order 1 g
    • Factory Site Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing
    • Price Inquiry sales7@sinochem-nanjing.com
    • Manufacturer Sinochem Nanjing Corporation
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    862481

    Name Mirabegron
    Brand Names Myrbetriq, Betmiga
    Drug Class Beta-3 adrenergic agonist
    Route Of Administration Oral
    Primary Indication Overactive bladder
    Mechanism Of Action Relaxes detrusor smooth muscle
    Common Dosages 25 mg, 50 mg once daily
    Metabolism Hepatic (mainly by CYP3A4, CYP2D6)
    Half Life 50 hours
    Side Effects Hypertension, nasopharyngitis, urinary tract infection
    Contraindications Severe uncontrolled hypertension
    Pregnancy Category Category C
    Approval Year 2012
    Storage Conditions Store at 20°C to 25°C (68°F to 77°F)
    Tablet Appearance Light brown, oval, film-coated tablet

    As an accredited Mirabegron factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Mirabegron packaging: White rectangular box containing 30 tablets; labeled with dosage (50 mg), manufacturer details, and safety information.
    Shipping Mirabegron is shipped in accordance with relevant safety regulations, packaged securely in certified, leak-proof containers. The chemical is protected from moisture and light and kept at controlled room temperature. Appropriate labeling is provided, and documentation accompanies each shipment for safe handling, legal compliance, and prompt delivery to authorized recipients.
    Storage Mirabegron should be stored at room temperature, typically between 20°C to 25°C (68°F to 77°F), away from excess heat, moisture, and light. Keep the medication in its original container, tightly closed, and out of reach of children and pets. Do not store in the bathroom or freeze. Proper storage helps maintain the efficacy and safety of the medication.
    Application of Mirabegron

    Applications of Mirabegron in Industrial Manufacturing

    Our Mirabegron raw material serves pharmaceutical manufacturers engaged in the development of advanced genito-urinary therapies. With strict adherence to regulatory standards and process controls, Mirabegron supports large-scale production demands for selective β3-adrenoceptor agonists, predominantly in the bladder dysfunction segment. Below, we outline specific industrial use cases, covering essential data from relevant compliance and formulation ranges, to integration in downstream operations and the types of finished goods produced by our global clients.

    1. Production of Extended-Release Oral Tablets for Overactive Bladder (OAB) Therapy

    Specialty pharma divisions utilize Mirabegron as the primary active pharmaceutical ingredient (API) in the commercial manufacture of once-daily extended-release tablets for adult and geriatric populations diagnosed with overactive bladder syndrome. As a direct β3-adrenoceptor agonist, Mirabegron enables improved patient adherence by supporting 24-hour symptom management, integrating robust excipient selection and process optimization to pass international release and stability testing standards.

    Industry compliance standards

    • ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
    • United States Pharmacopeia (USP) Monographs for Mirabegron
    • European Pharmacopoeia (Ph. Eur.) 11th Edition requirements
    • US FDA 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals)

    Typical usage ratio

    • API content per tablet: 25 mg or 50 mg, corresponding to a formulation inclusion level of 4-8% w/w, varying based on tablet mass and desired dissolution profile.
    • Excipients and matrix agents adjusted according to target pharmacokinetics; critical material attributes matched to commercial scale.

    Downstream process integration

    • Incorporated at the blending stage following final micronization and particle size reduction of API materials to ensure uniform content distribution.
    • Direct compression and wet granulation are used based on tablet designer requirements, followed by coating for controlled release dynamics.
    • Inline NIR/IR analysis validates content uniformity before packaging.

    Final product types

    • Extended-release oral tablets (25mg, 50mg OAB formulations branded and generic)
    • Clinical trial batches for equivalency and stability studies
    • Hospital bulk-pack oral solid dosage forms for institutional supply

    2. Manufacturing of Combination Oral Solid Dosage with Anticholinergics

    Global pharmaceutical manufacturers deploy Mirabegron in fixed-dose combination tablet formulations alongside antimuscarinic agents, offering dual-mode therapy for patients with suboptimal monotherapy responses. The co-formulation addresses regulatory requirements for impurity profile management and uniform dissolution kinetics, while production processes are tightly aligned with international co-formulation guidelines and validation protocols.

    Industry compliance standards

    • ICH M9 Biopharmaceutics Classification System-based Biowaivers
    • Japan Pharmacopoeia (JP XVII) for combination therapy inclusion
    • EMA Guidelines on Fixed Combination Medicinal Products
    • US FDA Quality by Design (QbD) principles in ANDA submission

    Typical usage ratio

    • Inclusion range: 25–50 mg Mirabegron per unit vs. 2.5–5 mg anticholinergic per unit; typical Mirabegron proportion is 5–12% w/w, contingent on final dosage size and clinical design.
    • Adjustment for exposure matching and impurity minimization monitored at pilot and validation batch stages.

    Downstream process integration

    • Mirabegron and antimuscarinic agent weighed and blended under segregated condition to limit cross-contamination risks.
    • Sequential granulation and tableting allow for precise API layering, inter-tablet uniformity, and dissolution control.
    • Final dosage blending and compression take place in air-controlled zones under high-efficiency filter protocols.

    Final product types

    • Co-formulated bilayer and monolayer oral tablets (Mirabegron with solifenacin or similar)
    • Regulatory submission and dossier samples for combination OAB therapy
    • Pre-market clinical supply batches assessed for interchangeability

    3. Contract Manufacturing for Generic ANDA/Biosimilar Market Supply

    Licensed API customers and generic medicine producers depend on our GMP-certified Mirabegron for the large-scale development of generic oral dosage forms intended for regulated markets worldwide. Our integrated batch release documentation and compliance with impurity profile requirements facilitate the rapid commercialization and legal defense of Abbreviated New Drug Application (ANDA) generics and biosimilar alternatives in competitive therapeutic segments.

    Industry compliance standards

    • WHO GMP guidelines for pharmaceutical production
    • US FDA ANDA filing standards for bioequivalence
    • European Medicines Agency (EMA) guidelines on generic approval
    • ICH Q3A/B (Impurities in New Drug Substances and Products)

    Typical usage ratio

    • Standard API loading: 5–10% w/w, targeting direct equivalence to innovator reference standards, with excipient selection tailored per market submission requirements and in-process controls.
    • Dose adjustment and excipient matrix calibrated to meet dissolution, friability, and stability requirements of target regulatory dossiers.

    Downstream process integration

    • API introduced following validated identification and particle quality audit; mixed with excipient base during master batch blending.
    • In-process quality control samples withdrawn for HPLC or UPLC quantitative analysis by QC/QA teams at the granulation and compression stages.
    • Final product passes through blister or bottle packaging lines under serialized and tamper-evident protocols.

    Final product types

    • Generic extended-release Mirabegron tablets for public and private healthcare channels
    • Bioequivalent OAB oral therapies for international market tenders
    • Bulk supply for multinational contract packagers and parallel importers

    4. Development of Pediatric and Geriatric Liquid Suspensions

    Specialty pharmaceutical units engaged in the creation of age-adapted OAB therapies integrate pharmaceutical-grade Mirabegron into oral suspension formats to address populations with dysphagia or solid dosage swallowing difficulties. Accurate dosing, low excipient toxicity, and stability are paramount, with process control extending to multi-point content verification to ensure safe administration, especially in institutional or home care settings.

    Industry compliance standards

    • United States Pharmacopeia (USP) <795> Pharmaceutical Compounding—Nonsterile Preparations
    • PIC/S Guide to Good Manufacturing Practice for Medicinal Products
    • EMA Reflection Paper on Formulations of Choice for the Pediatric Population
    • ICH Q1A(R2) Stability Testing of New Drug Substances and Products

    Typical usage ratio

    • API concentration: 1–4 mg/mL, adjusted by patient weight and age as per clinical protocols; typically, the API constitutes 0.2–1.5% w/v of the finished suspension.
    • Suspending agent and preservative types and levels modulated for palatability and microbial control in multi-dose packaging.

    Downstream process integration

    • Micronized Mirabegron suspended in aqueous or semi-aqueous base using high-shear mixing; pH and viscosity adjusted post-dispersion for long-term storage suitability.
    • Filling and capping automated in amber glass or HDPE container lines with nitrogen flush and in-process sampling for homogeneity.
    • Stability studies incorporate periodic sampling to confirm assay, uniformity, and preservative effectiveness throughout shelf life.

    Final product types

    • Pediatric and geriatric oral suspensions of Mirabegron for OAB management
    • Hospital in-house compounding bases for immediate dosing
    • Long-term care syrup or suspension formats for chronic use

    5. Analytical Reference Standards for Quality Control Laboratories

    Pharmaceutical quality assurance laboratories and analytical service providers use high-purity Mirabegron as the reference standard for identification, quantification, and impurity profiling of in-process and finished dosage samples. Certified reference material supports daily QC/QA monitoring and fulfills regulatory submission requirements during process validation, method development, and release testing activities for every batch destined for commercialization.

    Industry compliance standards

    • USP General Chapter <1225> Validation of Compendial Procedures
    • ISO/IEC 17025 General requirements for the competence of testing and calibration laboratories
    • ICH Q2(R1) Validation of Analytical Procedures
    • WHO guidelines on quality control of active pharmaceutical ingredients

    Typical usage ratio

    • Reference standard amounts per assay: 0.5–2 mg per HPLC or GC injection, prepared as per validated laboratory protocols. Working and stock solution concentrations are configured based on assay sensitivity and regulatory requirements.
    • Internal standard usage calibrated for method precision and reproducibility within each validated run.

    Downstream process integration

    • Supplied as certified, traceable material for calibration in release and stability testing of finished dosage and raw material lots.
    • Used in method transfer validation and routine batch release at production and independent contract labs.
    • Homogeneity and purity verified by NMR, LC-MS, or qNMR prior to batch clearance for use as primary or secondary standards.

    Final product types

    • Pharmaceutical QC laboratory assay kits and certified reference material vials
    • Analytical standards for stability and content uniformity studies
    • Method validation sets for regulatory dossier submission
    Free Quote

    Competitive Mirabegron prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615371019725 or mail to sales7@sinochem-nanjing.com.

    We will respond to you as soon as possible.

    Tel: +8615371019725

    Email: sales7@sinochem-nanjing.com

    Get Free Quote of Sinochem Nanjing Corporation

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Mirabegron: A Real-World Solution for Overactive Bladder

    Understanding Mirabegron’s Place in Everyday Care

    Living with overactive bladder comes with a unique set of frustrations. I remember talking to a friend who couldn’t sit through an entire movie at the theater without feeling anxious about the next bathroom run. His story echoes what so many people deal with day in and day out—frequent urges to urinate, sudden leaks, and the constant distraction that pulls you away from work, family, and just enjoying simple moments. That’s what initially drew my attention to Mirabegron. It’s not just another name on a pharmacy shelf; for many, it represents a shot at regaining daily comfort and confidence.

    What Sets Mirabegron Apart?

    Mirabegron is designed to address those exact bladder control problems by taking a very different approach than most older treatments. Traditional therapies usually go after the muscles directly, often with medications called antimuscarinics. People taking these often start reporting a dry mouth, constipation, or feeling a bit cloudy-headed. My own grandparents both tried several of those older options, and neither wanted to keep up with the side effects. Mirabegron works differently. It’s what’s known as a beta-3 adrenergic agonist. You won’t catch insiders talking in technical riddles, but, simply put, that means it targets a specific pathway to relax the bladder muscle and help it store urine more efficiently, with far fewer side complaints.

    Looking Beyond Specifications: Why the Model Matters

    In pharmacies, Mirabegron typically comes in easy-to-swallow tablets, with a most common strength being 25 mg or 50 mg. It isn’t the form or packaging that earns it its real value; it’s the way the medicine fits into modern life for people struggling with urgent bathroom trips. The design means users take it once daily, no constant pill reminders buzzing all day. It’s made for those who want simplicity. Dosage can be adjusted, especially if you have kidney or liver limitations, and I’ve seen clinicians appreciate that flexibility because life rarely fits into a single box.

    How Usage Translates Into Everyday Relief

    Managing an overactive bladder isn’t a casual concern. Anyone holding down a job, parenting small children, or traveling frequently doesn’t have the luxury of planning their life around a bathroom. Mirabegron tries to offer more freedom because the urge to run to the restroom, especially in public, falls away for many within a handful of weeks. The stories I’ve heard most often mention how routines start to feel normal again. Users don’t have to chug water at night just to avoid dry mouth, which plagues antimuscarinics, and that means better sleep and better days.

    How Mirabegron Grew From Research to Real Practice

    The backstory here matters, especially for those hesitant about new medicines. Mirabegron’s development came from looking at what people found difficult about established options. Research teams focused on not just how well a medication could work, but how a person could realistically live with it. Clinical studies included real life variables, evaluating not just the major fixes, such as fewer bathroom trips, but also side notes like less dry mouth and less constipation. The medical community took notice because the consistent findings showed benefit for people who couldn’t handle antimuscarinics at all. Since making its way onto pharmacy shelves, more doctors and patients have started using it, especially when older medications just didn’t work out or brought along too many hassles.

    Comparing Mirabegron to Older Treatments

    Most people start their search at the pharmacy with the familiar: oxybutynin, tolterodine, or solifenacin. These medicines address the muscle spasms that cause urgency and frequency, but they do so in a way that blocks important body signals. That leads to side effects people find hard to ignore, like a dry mouth that makes eating and drinking uncomfortable or troubles with constipation. I’ve heard stories of folks quitting their medicine because the fix was sometimes worse than the condition itself. Mirabegron sidesteps many of those complaints by taking another route. Instead of blocking signals, it helps the bladder muscle relax through a different system. It means people can usually stay on therapy longer, and aren’t choosing between comfort and control.

    Where Mirabegron Fits In: Real-Life Scenarios

    Let’s say you’re working as an elementary school teacher. You can’t leave a room full of children to dash off to the bathroom every hour. Or perhaps you’re caring for loved ones with mobility challenges, and every extra trip to the restroom means extra work, extra falls, and extra stress. Mirabegron steps in as an option for those living real lives, not clinical trials. I’ve known caregivers who found peace of mind using this medication—less risk, fewer accidents, better routines.

    Digging Into the Safety and Side Effects

    Every medicine comes with trade-offs, and Mirabegron is no exception, but the profile here looks gentler than what came before. The most common complaint tends to be a modest rise in blood pressure, and healthcare providers keep a close watch for that, especially in people with uncontrolled hypertension. Some users report headaches or mild urinary tract infections, though these happen less frequently than the classic issues seen with antimuscarinics. There’s also the question of how Mirabegron interacts with other medicines—especially ones broken down in the liver—so honesty in communication with your prescribing clinician is key. I find that most people appreciate a realistic heads-up up front, rather than running into surprise complications.

    A Glimpse at the Clinical Evidence

    Looking at the clinical trials, Mirabegron’s strengths stand out in how it improves frequency and urgency versus a sugar pill. For many, the improvements are clear within the first month of regular use. Much of the data shows not just symptom relief, but less interference with going about daily business, something folks with busy lives often highlight as the real win. The improvement isn’t just theoretical—it reflects in fewer embarrassing events at work or in public, and less time spent worrying about the next restroom.

    Cost and Access: The Practical Realities

    Price matters, and insurance hurdles can sometimes slow down access to Mirabegron. Compared to time-tested generics, the cost sits higher, and coverage policies vary widely. I’ve heard from several patients who struggle with these extra bills, so I always recommend checking with both your pharmacy and insurer before committing. Programs sometimes offer financial help, especially for those with difficulty affording newer options. Until more generics hit the market, this remains a sticking point for many families.

    Mirabegron in Special Populations

    Older adults sometimes shy away from medical change, especially if they already juggle several medications every day. The track record here supports its use in seniors, mainly because the light side effect profile means fewer disruptions. For those with mild to moderate kidney or liver problems, Mirabegron can still play a role, sometimes with adjusted dosing, which isn’t always possible with its older cousins. What always stands out to me is the conversations doctors have with patients—open, honest, and tailored, not just about the medicine, but about how it fits your life, your routines, and your goals.

    Mirabegron’s Role Beyond the Basics

    Mirabegron gained its reputation on overactive bladder, but there’s a budding interest in other uses. Researchers look at underactive bladders and combinations with other therapies, searching for better answers where single drugs fall short. Sometimes the best solutions build off what works, and recent studies point out that using Mirabegron alongside an antimuscarinic can offer extra relief for those who just don’t get results from one alone. These sorts of options can be game changers for select people—especially those whose bladders refuse to cooperate with anything else.

    My Own Experience in Discussing Choices

    I’ve had dozens of conversations with folks at different stages of dealing with bladder problems. What stands out most isn’t which medicine ends up on the prescription pad—it’s the relief people feel when they’re finally heard. Mirabegron keeps coming up as the next step when everything else stalls out. Some people report modest changes, while others say it was the first medicine that let them get through an entire day out with friends or sleep through the night. The medicine won’t fix everything, and expectations should stay grounded, but seeing people regain control of everyday life makes a difference.

    Barriers to Wider Use—and Possible Solutions

    No medicine solves a problem if people can’t get it, either due to price or lack of knowledge. Open conversations with providers and pharmacists go a long way in making sure that Mirabegron ends up in the hands of those who need it most. Education also matters—both for clinicians who have leaned on the old standbys for years, and for patients who may not have heard about newer options. Pharmaceutical companies and advocacy groups can team up to improve awareness and develop programs that cut through the red tape. Efforts in telemedicine and electronic health record prompts could nudge clinicians to bring up Mirabegron when reviewing bladder complaints, making sure it doesn’t get lost in the shuffle.

    The Social Toll—A Broader View

    Overactive bladder creates more than medical stress—it saps confidence and undercuts enjoyment in social situations. Anyone who’s skipped a family outing or avoided travel knows the shadow it casts. Relief from these symptoms isn’t just about comfort—it brings dignity back to daily life. Medicines like Mirabegron open doors for people who have quietly put limitations on themselves for years. When I talk to people finally finding relief, it often allows them to pick up old hobbies, reconnect with friends, or simply go out for dinner without scouting the position of every public restroom.

    Safety in the Real World

    Clinical trials lay the groundwork, but real-world monitoring matters just as much. After years on the market, Mirabegron continues to show a safety record that supports expanded use, but vigilance stays key. Providers check blood pressure and monitor for any unusual side effects, building in a layer of safety that reassures worried patients. This isn’t about playing defense—it’s about making sure the improvements in daily life never come at the expense of longer-term health.

    Mirabegron and Long-Term Outlook

    The path to regaining a sense of control doesn’t finish with the first pill. Patients and providers work together over months, tweaking doses or making changes as needs evolve. In my view, the most important gains with Mirabegron show up over time, as people reflect and realize just how much more freedom they feel. For those who were ready to quit on treatments, giving Mirabegron a try sometimes shifts the whole picture—work gets easier, relationships relax, and personal confidence rebuilds.

    Community and Peer Support: A Key Ingredient

    Online forums, local support groups, and informational sessions all play a part in spreading news about what works. Those who’ve found help through Mirabegron often share their first-hand stories, turning the spotlight on small victories—a full night’s sleep, an uninterrupted meeting, a day at the park with kids or grandkids. These shared experiences carry weight when deciding what to try next. I’ve watched hesitant patients take a leap because someone else’s story mirrored their own.

    Opportunities for Innovation

    Even as Mirabegron gains ground, opportunities remain. Better education for primary care doctors, wider insurance coverage, smarter patient-clinician conversations, and ongoing research into combined therapies all stand to maximize benefits. Medicines like Mirabegron show us medicine isn’t just about technical advances, but about delivering relief people feel in their everyday lives. Expanding research and community dialogue can only help more people find the right fit for their unique needs.

    Mirabegron’s Place in the Conversation

    At the center of so much chatter about new drugs, Mirabegron offers a practical solution that values patient comfort, daily function, and a better quality of life. Some might still face insurance hang-ups or price obstacles, but advocacy and transparent dialogue with healthcare teams can sometimes break down those barriers. I’ve watched Mirabegron shift the conversation from just masking symptoms to helping reclaim regular routines, restoring both comfort and confidence. Bladder problems won’t disappear with one solution, but Mirabegron brings new hope to a challenge that’s often suffered in silence.

    Moving Forward: The Need for Better Access and Awareness

    Pushing for broader coverage and improved education for both medical teams and patients remains a vital part of the picture. Success stories matter, and the steady rise of Mirabegron points toward greater acceptance and more personalized care options. With the right support and persistence, people living with overactive bladder can find relief that doesn’t just show up in lab tests, but in richer, freer day-to-day living. Health doesn’t just mean the absence of symptoms—it means getting your life back. Mirabegron aims to make that possible for more people, one real-life story at a time.